Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Rina-S · 8 trials · 22 indications
PFS is defined as the time from the date of randomization to the date of the first documented progression or death (PD) due to any cause, whichever occurs first based on response evaluation criteria in solid tumors (RECIST) version 1.1 as assessed by the investigator.
The proportion of participants experiencing DLT.
Participants who achieve partial response (PR) or complete response (CR) per RECIST v1.1 criteria.
| Arm | Type | Description |
|---|---|---|
| Arm 1: Rina-S ± Bevacizumab | EXPERIMENTAL | Participants will receive Rina-S ± bevacizumab once every 3 weeks (Q3W). |
| Arm 2: Investigator Choice of Chemotherapy ± Bevacizumab | ACTIVE_COMPARATOR | Participants will receive carboplatin plus gemcitabine ± bevacizumab, carboplatin plus paclitaxel ± bevacizumab, or carboplatin plus pegylated liposomal doxorubicin (PLD) ± bevacizumab. |
| Rina-S | EXPERIMENTAL | - |
| Investigator's Choice | ACTIVE_COMPARATOR | - |
| Rina-S + SOC | EXPERIMENTAL | Participants will receive Rina-S and SOC consisting of either bevacizumab maintenance or no maintenance treatment (observation). |
| SOC | ACTIVE_COMPARATOR | Participants will receive SOC consisting of either bevacizumab maintenance or no maintenance treatment (observation). |
| IC | ACTIVE_COMPARATOR | Participants will receive one of the following chemotherapies at the discretion of the investigator: * Paclitaxel on Days 1, 8, and 15 every 4 weeks (Q4W). * Doxorubicin on Day 1 Q3W. |
| Part A, B, C, E, F, G, H, I, J and K | EXPERIMENTAL | Rina-S monotherapy in Part A and at the recommended dose in Parts B, C, E, F, G, H, I, J and K. |
| Part D1 | EXPERIMENTAL | Rina-S in combination with carboplatin |
| Part D2 and I | EXPERIMENTAL | Rina-S in combination with bevacizumab |
| Part D3 and D4 | EXPERIMENTAL | Rina-S in combination with pembrolizumab |
| Name | Type | Description |
|---|---|---|
| Rina-S | BIOLOGICAL | Intravenous (IV) infusion |
| Bevacizumab | DRUG | IV infusion |
| Carboplatin | DRUG | IV infusion |
| Gemcitabine | DRUG | IV infusion |
| Paclitaxel | DRUG | IV infusion |
| PLD | DRUG | IV infusion |
| Topotecan | DRUG | IV infusion |
| Pegylated liposomal doxorubicin (PLD) | DRUG | IV infusion |
| IC | DRUG | * Paclitaxel: IV infusion * Doxorubicin: IV bolus injection/infusion |
| Pembrolizumab | DRUG | Pembrolizumab intravenous infusion |
Key Inclusion Criteria: * Participant must have histologically confirmed high-grade serous or endometrioid epithelial ovarian cancer (EOC), including primary peritoneal or fallopian tube cancer. * Participant must have documented recurrence or progression after first-line (1L) platinum-based chemot...
Top 20 of 46 competitors
Rina-S is an investigational oncology drug being developed for multiple cancer types, including platinum-resistant ovarian cancer, high grade epithelial ovarian cancer, endometrial cancer, gastrointestinal cancers, and non-small cell lung cancer (NSCLC). It is currently in Phase 3 clinical development for platinum-resistant ovarian cancer.
Rina-S is being developed by Genmab A/S, a biopharmaceutical company traded on the Nasdaq under the ticker GMAB. The company is conducting clinical trials for Rina-S across multiple oncology indications, including ovarian cancer and non-small cell lung cancer.
Rina-S is in Phase 3 clinical development for platinum-resistant ovarian cancer, with an active Phase 3 trial (NCT06619236) comparing it to investigator's choice treatment. It is also being studied in Phase 2 for non-small cell lung cancer and in earlier-stage trials for other solid tumors.
Rina-S is being evaluated in multiple trials, including NCT05579366 (Phase 1, advanced solid tumors), NCT06619236 (Phase 3, platinum-resistant ovarian cancer), NCT07225270 (Phase 3, recurrent platinum-sensitive ovarian cancer), and NCT07288177 (Phase 2, non-small cell lung cancer). All trials are actively recruiting or ongoing.
Yes, Rina-S is also known as PRO1184 and GEN1184, as indicated in the Phase 1 trial title for advanced solid tumors. These alternative names refer to the same investigational drug being developed by Genmab.
Rina-S is a small molecule oncology drug, but its specific molecular target has not been disclosed in the available clinical trial information. It is being studied across multiple cancer types, suggesting a potentially broad antitumor activity, though the exact mechanism remains under investigation.